STRYKER CORPSYK
STRYKER CORP Financial Overview 2021–2025
Stryker delivered a massive 32.5% surge in operating income in FY2025, significantly outpacing its 11.2% top-line growth. This operational leverage underscores the company’s successful pivot toward high-margin MedSurg and Neurotechnology segments while effectively managing aggressive M&A integration. The company’s relentless acquisition strategy has fueled a steady trajectory, with net sales climbing from $17.1 billion in FY2021 to $25.1 billion in FY2025.
The portfolio shift is evident in recent performance; MedSurg and Neurotechnology sales jumped 15.7% in FY2025, bolstered by the $4.94 billion acquisition of Inari Medical to expand vascular offerings. Conversely, the legacy Orthopaedics segment grew a modest 4.3%, prompting the strategic divestiture of the US Spinal Implants business to refine the asset mix. Despite heavy investment, Stryker defended profitability with a 64.0% gross margin and generated $5.04 billion in operating cash flow. Investors have priced this consistent double-digit execution at a premium, with the stock trading at 41.8x earnings at the close of FY2025.
Recent Developments (Q3 and Q4 2025)
In Q3 2025, Stryker reported net sales of $6.06 billion, a 10.3% year-over-year increase, while diluted EPS grew to $2.22 compared to $2.16 in the prior-year period. Beyond the financials, the company restructured its executive leadership team in December 2025, promoting Spencer Stiles to President and Chief Operating Officer and Dylan Crotty to Group President of Orthopaedics. Management also maintained its commitment to shareholder returns, declaring total dividends of $3.36 per share for the fiscal year.
Bullish investors point to the 9.6% constant currency growth in Q3 2025 as evidence that underlying demand remains robust despite macroeconomic pressures. However, bears note that operating margins experienced slight compression in the third quarter due to elevated integration costs. As of February 10, 2026, the stock traded at 43.3x earnings, a valuation that implies high expectations for the new leadership team’s ability to drive efficiency.
What to watch: Margin recovery following recent integration expenses; execution of the new COO's operational strategy.
Rev
$25.12B
FY2025
NI
$3.25B
FY2025
EPS
$8.49
FY2025
OCF
$5.04B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
STRYKER CORP 8-K Report, Financial Results (Jan 29, 2026)
Stryker Corporation (SYK) has filed an 8-K report on January 28, 2026, to announce its fourth quarter and full-year 2025 operating results and provide its outlook for 2026. This filing primarily directs investors to a press release, included as Exhibit 99.1, which contains the detailed financial performance and future guidance. Investors should refer to this press release for comprehensive information regarding the company's recent financial health and its strategic expectations for the upcoming fiscal year. The information presented is furnished and not deemed 'filed' for regulatory purposes, underscoring the importance of reviewing the press release directly.
STRYKER CORP 8-K Report, Executive Changes (Dec 4, 2025)
Stryker Corporation (SYK) announced significant leadership changes effective January 1, 2026. Spencer Stiles, currently Group President of Orthopaedics, will be promoted to President and Chief Operating Officer. Dylan Crotty, previously President of Instruments, will succeed Mr. Stiles as Group President, Orthopaedics. Both executives have long tenures with the company and have held various leadership roles across key business segments. These executive appointments come with updated compensation packages, including base salary increases, bonus targets, and recommendations for substantial long-term incentive awards for both Mr. Stiles and Mr. Crotty in early 2026. The compensation details include a mix of stock options and performance stock units, reflecting a commitment to retaining and incentivizing key leadership talent. Investors should note these moves signal continued internal development and a focus on experienced leadership within Stryker's operational structure.
STRYKER CORP 8-K Report, Financial Results (Oct 30, 2025)
Stryker Corporation has filed an 8-K report on October 30, 2025, to announce its third quarter 2025 operating results via a press release dated October 30, 2025. This filing serves as the primary vehicle for disclosing the company's financial performance for the period ending on or around September 30, 2025. Investors should refer to the attached press release (Exhibit 99.1) for detailed financial figures, operational achievements, and forward-looking statements that were shared by the company. The information furnished within this report, specifically the press release, is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any other SEC filings unless explicitly stated. This means the standard liability provisions for filed documents do not apply to this particular disclosure. Investors are encouraged to review the press release for a comprehensive understanding of Stryker's Q3 2025 performance and any associated commentary from management.
STRYKER CORP 8-K Report, Financial Results (Jul 31, 2025)
Stryker Corporation (SYK) has filed an 8-K report on July 30, 2025, to announce its second quarter 2025 operating results via a press release dated July 31, 2025. While the full details of the results are contained within the attached press release (Exhibit 99.1), this filing serves as formal notification to the market. Investors should refer to Exhibit 99.1 for specific financial performance, key operational achievements, and management commentary regarding the second quarter. The company is providing this information as required, and the details within the press release will offer insights into Stryker's performance, including revenue, profitability, and any forward-looking statements or guidance provided by management. It's important for investors to review the attached exhibit for a comprehensive understanding of the company's recent financial condition and operational outcomes.
STRYKER CORP 8-K Report, Executive Changes (May 13, 2025)
Stryker Corporation (SYK) held its Annual Meeting of Shareholders on May 8, 2025, where significant corporate governance and compensation-related proposals were approved. The most notable outcomes include the shareholder approval of the amended and restated 2011 Long-Term Incentive Plan, the 2011 Performance Incentive Award Plan, and the 2008 Employee Stock Purchase Plan. These approvals allow for an increase in the number of shares available for issuance under these plans and extend their durations, which is crucial for ongoing employee compensation and retention strategies. Additionally, all ten incumbent directors were re-elected, demonstrating continued shareholder confidence in the current board's leadership. The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was also ratified. The advisory vote on executive compensation also received shareholder approval. These outcomes indicate shareholder alignment with the company's governance and compensation frameworks, suggesting stability and continued support for management's strategic direction.
View all 8-K filings →